Pin down where the product sits inside the YY 0285 family
Many companies treat "test it to YY 0285" as an instruction that can be issued in a single sentence, only to find when the test request form is opened that the number covers a family: general requirements plus particular requirements for catheters of different intended uses. When the test list cannot be written, the cause is usually not that the standard was read too lightly, but that the product definition was never pinned down.
Before submission, answer five questions in writing. The answers determine the scope of the test list directly.
- What is the clinical use of this catheter: angiography, drug delivery, indwelling infusion, or acting as an access route for another device?
- Is the delivered item a single catheter, or a kit containing introducer, dilator, guidewire and connecting tubing?
- Structurally, does it have coatings, braided or coil reinforcement, radiopaque markers, side holes, multiple lumens?
- In use, is contact with circulating blood direct or indirect through an access route, and does that contact persist through the whole indwelling period?
- What contact site, contact medium and indwelling duration category do you intend to declare on the label?
The last two questions are the ones most often skipped. The mode of blood contact decides whether endpoints in the blood interaction direction have to be opened up in the biological evaluation. The indwelling duration category is not a marketing phrase either: it sets both the depth of the biological evaluation pathway and the timeline of the stability studies. Change the product definition and a whole block of completed evaluation work may become void.
Regroup the items by failure mode instead of copying the contents page
The YY 0285 family is organised by clause. Submission preparation, however, is organised around a different question: can this sample satisfy this item? Regroup the items by the failure question each one answers, and it becomes obvious which items have to share one batch of samples and which items destroy samples for one another.
| Item group | What this group answers | Sample state required | Common reason for rejection |
|---|---|---|---|
| Appearance and surface, particulate contamination | Are there processing defects or sheddable matter | Finished product with the original sterile barrier unopened | Bulk or already opened samples arrive, and contamination introduced by the environment cannot be separated from the product's own |
| Dimensions and consistency with declared values | Does the label declaration match the physical item | Same batch as the label and the instructions for use | Only the product is sent, without label and IFU artwork, so declared values cannot be checked |
| Connection and strength | Can the connector interface withstand handling loads | Complete assembly including matching connectors and accessories | Accessories missing or supplied later, so the joint cannot be assembled in its actual in-use state |
| Pressure resistance and burst | Where the wall and the septum fail under internal pressure | Complete flow path in its real form, including side holes and multi-lumen construction | A shortened piece is substituted for the whole catheter, so failure locations are not comparable |
| Flow rate and patency | Is the lumen affected by coating, burrs or residues | Sterilised finished product with the coating in its declared in-use state | Unsterilised semi-finished parts substituted, so the coating state differs from the finished product |
| Leakage and sealing | Do sealing interfaces fail under positive and negative pressure | Complete flow path with all valves and clamps in place | Valves supplied separately, so the assembly differs from the as-shipped condition |
| Radiopacity and guidewire passage | Image discernibility and real usability of the lumen | Same formulation and same production batch as the mechanical samples | Radiopacity samples and mechanical samples come from different formulations and the data contradict each other |
| Chemical performance | What level of extractables the extract contains | Fully sterilised and aerated product in its original packaging | Sent before the aeration process has been completed |
| Biological evaluation | Is contact with the body safe | Finished product, or a justified equivalent representative sample | Old sample data still relied on after a material or process change |
| Evaluation in the blood contact direction | Will contact with circulating blood cause haemolysis, abnormal coagulation or thrombus formation | Whole catheters or complete segments matching the real contact surface and flow path; sample demand far higher than for other biological items | Only a short piece of tubing is sent, so neither contact area nor flow path represents the actual product |
| Sterility and endotoxin | Are sterilisation and production environment controls effective | Sterile barrier intact and undamaged in transit | Packaging damaged in transit, so the sample is simply unusable |
No limit values appear in this table, and that is deliberate. Specific parameters and acceptance limits are governed by the current valid version of the standard text; when running an internal check, work from a controlled copy of the standard rather than a second-hand summary.
Chemical performance and biological evaluation are two lines, and neither substitutes for the other
This misunderstanding recurs constantly in catheter submissions. The YY 0285 family points to both lines within the product requirements, but their roles are completely different. The GB/T 14233 series provides the methodological basis for chemical analysis and biological tests, and what it produces are chemical indicators at the extract level, in directions such as acidity and alkalinity, reducing matter, heavy metals, evaporation residue, ultraviolet absorbance and sterilant residues. Those methods sit in different parts of that series, and which part governs a given test and which edition applies are determined by the current valid version of the standard text. The GB/T 16886 series and the ISO 10993 series, by contrast, are evaluation frameworks: first plan the evaluation pathway according to the nature and duration of contact, then decide which tests have to be run and which can be replaced by existing data and chemical characterisation.
How extraction conditions are set, and how the chemical line and the biological line are joined together in the submission dossier, is a cross-product methodology question handled in a separate article on extraction logic, so it is not expanded here. One conclusion is worth keeping: the extraction media, extraction ratios and extraction conditions of the two lines have separate origins, and an extract prepared for one line cannot be used to satisfy the requirements of the other.
Intravascular catheters cannot avoid the blood contact direction
Planning the pathway along the lines of ISO 10993-1 starts by categorising the product. An intravascular catheter is generally categorised in the evaluation pathway as an externally communicating device in contact with circulating blood, the contact medium being blood and the contact duration filed according to the indwelling category declared on the label. The categorisation conclusion for a given product is whatever the confirmed evaluation pathway states. Once the categorisation is fixed, the endpoints to be addressed are largely framed.
Cytotoxicity and sensitisation are almost unavoidable, corresponding to ISO 10993-5 and ISO 10993-10. Beyond those, because the product sits in the blood flow path throughout use, endpoints related to interaction with blood are normally planned as well. The usual areas of concern include whether blood cells are damaged (haemolysis), whether the coagulation process is abnormally activated, whether platelets are adhered and consumed, whether the complement system is activated, and whether the device surface induces thrombus formation. These areas are specified in the corresponding parts of the ISO 10993 and GB/T 16886 series; which part carries which topic, which edition applies and which sub-items have to be opened up are governed by the current valid version of the standard text and by the confirmed evaluation pathway. Do not write the test order from a second-hand summary.
This group of endpoints places two extra demands on submission preparation, and they are worth stating separately.
Sampling differs from other biological items. A substantial part of the blood interaction direction consists of direct contact tests, and the test design has to reflect the real contact surface and flow path between device and blood. That usually means submitting whole catheters, or complete segments cut to the declared length, rather than a piece of tubing snipped off at random. Coated sections, sections carrying side holes and sections carrying radiopaque markers cannot be excluded from the sampling range, otherwise what is tested is not the real contact interface.
Sample demand is larger than expected. Direct contact tests usually need a number of parallel samples, and once controls and possible retests are added the consumption often exceeds the total of all other biological items. Leaving the blood contact direction off the test list does not just mean one missing test; it means the whole sample quantity estimate has to be rebuilt. This is one of the main reasons products of this type end up adding samples on the day the order is placed and slipping the schedule.
Confirm the full scope of the evaluation pathway against the item directions on the biocompatibility testing page rather than waiting for a review deficiency to raise it.
One reminder: presenting a chemical performance report in answer to a biological evaluation requirement, or using cytotoxicity results to argue that extract chemistry is acceptable, does not stand up in a submission. Their sampling, extraction conditions and decision logic were never the same thing.
Failure-prone items seen from load paths and mass transfer
What follows is engineering analysis based on structural mechanics and mass transfer, used to explain why failures happen. It is not a statistical conclusion about any particular product, and it does not replace measurement.
Peak tensile force at the hub-to-shaft joint. The load path runs from the external force applied at the hub, through the bonded or welded interface into the tube wall, and then axially along the wall. Stiffness changes abruptly at the interface, so stress concentrates there by definition; wall thickness transitions, the ends of reinforcement layers and the edges of radiopaque markers are equally points of geometric discontinuity. That explains a common pattern in which pilot samples pass and production samples fail. Interface strength is governed by adhesive quantity, cure conditions and whether surface treatment was performed, and those process parameters are quietly changed on the way from pilot to production while the drawing looks identical. If production samples are submitted without a process change statement, a failure is very hard to localise.
Pressure resistance and burst. During contrast injection or pressurised delivery, the wall carries hoop stress generated by internal pressure, and hoop stress rises as inner diameter increases and falls as wall thickness increases. For a given material, enlarging the inner diameter to gain flow lowers pressure capability at the same time: flow and pressure resistance are opposing design constraints, and a fair number of test failures are effectively written in at the design stage. In multi-lumen catheters the septum is usually the weak surface, and burst often initiates there rather than at the outer wall. In products with side holes the hole edge is a stress concentration and cracks usually start there. Do not discard burst samples: the failure location tells you far more about what to change than a pass or fail line does.
Flow rate and static leakage. The flow item measures the combined resistance of the whole path, and lumen diameter, effective length, side hole openings and cross-section changes inside the hub all count. A frequent source of deviation in practice is the coating: once a hydrophilic coating is wetted, both its thickness and its friction state change, so results from dry samples do not match the clinical condition. Static leakage examines the sealing interfaces, that is, whether valves, hub tapers and bond lines seep while pressure is held. The two items share complete flow path samples, but flow is essentially non-destructive while leakage may leave irreversible deformation, so run flow first and leakage second; the reverse order costs an extra batch of samples.
Radio-detectability. Radiopacity is achieved by loading the base material with high atomic number filler or by embedding a marker, and raising the filler proportion changes the mechanical behaviour of the material, typically raising modulus and lowering toughness. Hence a classic trade-off: raising the filler proportion for a clearer image degrades kink resistance and peak tensile force together. If radiopacity samples and mechanical samples are submitted in different batches with different filler ratios, the two data sets contradict each other in ways that are hard to explain during review.
Guidewire passage and kink resistance. Guidewire passage examines whether the lumen is actually usable, and residues, burrs, coating build-up and local collapse of the inner wall all show up as increased passage resistance. Lumen collapse is fundamentally a cross-sectional instability of a thin-walled tube under bending, and resistance to it is related to wall thickness, material modulus, and the braid angle and coverage of the reinforcement layer. There is an easily missed coupling here: material modulus drifts with the sterilisation process and with ageing, and in coated products the surface properties change once the coating takes up water. Evaluating kink and passage behaviour on unsterilised samples therefore does not necessarily extrapolate to the finished product.
Sterilant residues. Residue desorption is a diffusion-controlled process, and the solubility and diffusion coefficient of the residue in the material set the rate. Thick-walled catheters, multi-layer composite constructions and designs with enclosed internal cavities have long desorption paths, so they need longer aeration than thin-walled single-layer products. Sending samples for chemical performance testing before the aeration process is complete produces predictably high results, and that is not a testing problem. Work out the sterilisation process and the aeration schedule against sterilisation testing services first, then set the submission date.
Samples and packaging: only the catheter-specific part
The general ground rules for sample quantity, state and size coverage are already set out on the sample submission requirements page and are not repeated here: estimate quantity as number of items multiplied by parallel samples required and by the number of sizes to be covered, with margin for retests; the state must be finished product that has been through the complete production, sterilisation and aeration process; coverage is grouped by structural difference rather than by model count. Packaging and stability form a timeline of their own, separate from product performance testing. Sterile barrier system validation framed by ISO 11607 needs its own samples, and ageing samples have to be started early; for scheduling and sample commitment see packaging validation. Only one point needs stressing here: the packaging format should be frozen at the same time as the product definition, otherwise the performance reports will be finished and the registration timeline will still be held up by shelf life studies.
For intravascular catheters specifically, three things need confirming before the order is placed.
- Group size coverage by flow path construction. Products differing in lumen count, reinforcement type, presence of coating or presence of side holes generally cannot represent one another. Products differing only in colour, or in length within the same structural platform, can usually be grouped with a written statement. The rationale for grouping has to be submitted in writing with the samples, because reviewers look at the rationale, not just the conclusion.
- Send kits complete, in as-shipped assembly. Introducer, dilator, guidewire, connecting tubing, valves and clamps all have to be present if they are delivered with the product. Connection strength, leakage and flow all depend on the real assembled interface, and supplying accessories later means re-running the tests.
- List blood contact samples as a separate line. These samples can neither be shared with destructive mechanical items nor replaced by unsterilised parts, and the quantity has to be added on top of the general estimate, otherwise the project runs out of samples half way through. Packaging validation samples and product test samples should also come from the same traceable production batch, since mixing batches leaves a gap in data consistency that is hard to explain.
Pre-submission self-check list
- Are the product definition, clinical use, mode of blood contact and indwelling duration category fixed in a written document?
- Is the rationale for flow path grouping written up in a form that can be submitted?
- Are introducer, dilator, guidewire, valves and other supplied components present in as-shipped condition?
- Are blood contact samples estimated and reserved separately, rather than being consumed by mechanical items?
- Do the radiopacity, mechanical and chemical samples come from the same filler formulation and the same production batch?
- Are the samples finished product after complete sterilisation and aeration, with the sterile barrier intact?
- Are the chemical, biological and packaging lines scheduled in parallel?
- Are the standard texts you cite controlled copies of the current valid versions rather than second-hand summaries?
What SUNGO Lab can do for intravascular catheter projects
SUNGO Lab operates laboratories in Shanghai and Hefei and can take on physical performance, chemical performance, biological evaluation and packaging validation work for intravascular catheter products. At project start-up we can also help sort out the test list, the evaluation directions matching the blood contact route, the sample grouping plan and the sample quantity estimate, so that fewer additional samples are needed later. The laboratory is accredited by CNAS, CMA and IAS (USA). Please note that an accreditation mark only demonstrates that the laboratory is technically competent within its accredited scope and does not constitute a commitment regarding market access outcomes; registration and access conclusions still rest with the review opinions of each country's regulator. Related material is collected under technical knowledge.
For the exact item scope, turnaround and sample requirements, contact us with your product structure drawings and the label claims you intend to make. Call +86 132 4819 8029, or request a quote, and we will put together a submission plan built around your product definition.